SCHEMBL3085196

SCHEMBL3085196

CCOC(=O)C(CC(=O)NCc1ccccc1)(C(=O)OCC)C(=O)OCC

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.60
PPID Q08752 1/20 0.57
LMNA P02545 1/20 0.53
KMT2A Q03164 4/20 0.51
MEN1 O00255 2/20 0.51
TP53 P04637 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 1/20 0.49
RECQL P46063 1/20 0.49
MMP8 P22894 1/20 0.49
EPHX2 P34913 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.49
NAMPT P43490 1/20 0.48
HPGD P15428 1/20 0.48
RIPK1 Q13546 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103941 0.79 MAPT (0.53) MAPTKMT2AMEN1TP53SMN1; SMN2
SCHEMBL2087667 0.78 PPID (0.68) MAPTPPIDLMNAKMT2AMEN1
SCHEMBL406479 0.76 LMNA (0.71) LMNAKMT2AMEN1MMP8EPHX2
SCHEMBL423344 0.76 PPID (0.64) MAPTPPIDLMNAKMT2AMEN1
SCHEMBL5806489 0.76 ALDH1A1 (0.62) MAPTPPIDLMNAKMT2AMEN1
Benzene SCHEMBL8878788 0.76 PPID (0.64) MAPTPPIDLMNAKMT2AMEN1
SCHEMBL3088690 0.76 PKM (0.39) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL14782920 0.75 PPID (0.56) MAPTPPIDLMNAKMT2AMEN1
SCHEMBL23080143 0.75 RIPK1 (0.57) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL2171018 0.74 PPID (0.66) MAPTPPIDLMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 MAPT 2813/4885PPID 3650/4885LMNA 3803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.